 goal achiev pipelin success
continu commerci execut view
messag perhap biggest take-away apart better-than-expect sale
guidanc forecast oper margin pharma busi
bench talent busi develop head
introduc investor sale ep growth forecast
respect driven sale leverag rate buy
pt result estim chang
compani
diabet portfolio mani year growth ahead enriqu conterno presid
diabet palpabl enthusiasm sustain growth trulic class
bolster chief scientif offic dr skovronski view glp/gip could
significantli expand class announc plan start ph trial obes new
ph trial nash acceler develop program one main driver lli
acceler expand spend plan new guidelin recommend
specif highlight cv benefit jardianc agent
increment distanc jnj cs invokana safeti issu upcom
trial heart failur benefit jardianc ultim class time
biomedicin growth pois expand olumi mirukizumab underappreci
pam one watch head biomedicin christi shaw emphas breadth
depth lli immunolog growth pain portfolio perhap best
industri management expect new indic taltz olumi jak
neutral expand us global growth agent pleasantli
surpris dr lotu mallbri vice-president immunolog develop learn
seek refil mg dose ra us fda safeti
efficaci databas expand indic use mg dose quickli grow
europ dr mallbri also emphas opportun lli mirukizumab high-
affin potenti best-in-class agent ulcer coliti addit
emphas recent chang fda rais bar crohn diseas
believ lli agent deliv robust outcom year ph dataset read
lupu see compel opportun work fda fast track design
care design develop olumi first oral corticosteroid spare therapi
well monotherapi treatment option time pain market opportun
emgal receiv consider attent tanezumab safeti profil major focu
discuss said continu view upcom patient oa safeti studi
defin event drug outsid tanezumab lli dr gudarz davar vice-president
neurolog develop highlight opportun novel posit alloster
modul pam believ uniqu approach modul dopamin valid
target could significantli benefit cognit patient parkinson alzheim
oncolog leadership uniqu focus bd report cso
oncolog busi led ann white expect continu growth busi
end driven cyramza verzenio alimta loss alimta
us team uniqu focus advanc acceler develop lli
intern pipelin acknowledg strong focu near- medium-term busi
develop interestingli management note part overal busi reorgan
priorit busi develop report cso skovronski dr
skovronski ms white emphas strong interest target therapi well
new platform oncolog management uniqu focus core compet
develop way add valu ph asset work advanc new platform
technolog pace faster histor move antibodi fusion protein
develop take-away continu expect remain activ
bd particular focu oncolog across rang potenti asset see
page analyst certif import disclosur
greatest valu opportun advanc earli stage asset continu evalu
later stage option either purchas partner later stage asset
model updat reflect higher growth key driver partial off-set
 fx impact revenu estim near mid-point management
lli revenu rang assum mid-singl digit revenu growth
fx headwind lower gross margin bp
reflect mgmt assumpt neg loe impact price off-set inventori fx tailwind
op ex estim touch mid-point mgmt rang driven
primarili increas expens result time number phase trial
cost net-net forecast ep mid-point mgmt
view long-term guidanc achiev lli sale guidanc call
minimum compound-annual-growth-rate exclud pharma busi impli sale
north human pharma busi despit intensifi competit
lli key therapeut categori mainli diabet immunolog compani long-
term guidanc point continu strong uptak newer product includ trulic
taltz jardianc well impli expect anti-cgrp antibodi emgal
view achiev given continu strong volum market share growth
continu see key driver tanezumab long-term safeti efficaci studi
remain largest near-term potenti catalyst see emgal anti-cgrp
migrain tirzepatid diabet obes meaning contributor
medium- long-term combin sale contribut model
potenti catalyst top-line phase data baricitinib atop dermat
tanezumab long-term osteoarthr chronic lower back pain data regulatori
action emgal galcanezumab episod cluster headach regulatori action
lasmiditan acut migrain full separ elanco anim health
page analyst certif import disclosur
valuat risk
dcf price target result chang profit
loss forecast sale use larg pharmaceut compani discount
rate termin growth rate
downsid risk includ sustain price pressur diabet immunolog
higher-than-expect rate seriou advers event rpoa long term safeti studi
page analyst certif import disclosur
usd million except ep
compani report guggenheim llc estim
page analyst certif import disclosur
usd million except ep
compani report guggenheim llc estim
page analyst certif import disclosur
